Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Joan Bladé, Isidro Jarque et al.|Blood|2023Cited by 62
Mass spectrometry vs immunofixation for treatment monitoring in multiple myelomaNoemí Puig, María‐Victoria Mateos, María-Teresa Contreras et al.|Blood Advances|2022Cited by 53